← Back to Search

Genotype-Guided Diet and Exercise for Cardiometabolic Health

N/A
Recruiting
Led By Pankaj Arora, MD, FAHA
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age more than or equal to 18
Consent to the collection of genetic material
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 days
Awards & highlights
No Placebo-Only Group

Summary

This trial will study how well natriuretic peptides (hormones produced by the heart) work in people with a genetic variation that causes lower levels of these peptides.

Who is the study for?
This trial is for adults over 18 without a history of severe heart conditions like congestive heart failure, heart attack, or stroke. Participants should not be on insulin therapy but must be willing to follow the study protocol and consent to genetic material collection.
What is being tested?
The GENESIS study is looking at how diet and exercise affect hormones produced by the heart called Natriuretic Peptides (NP), which are linked to cardiometabolic health. It will involve an exercise challenge, glucose challenge, and VO2 max determination.
What are the potential side effects?
Since this trial involves dietary changes and physical challenges rather than medication, side effects may include muscle soreness from exercise or discomfort from dietary adjustments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I agree to provide samples for genetic testing.
Select...
You agree to follow the rules of the study.
Select...
I have never had heart failure, a heart attack, or a stroke.
Select...
I do not take insulin.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Correlation of resting miR-425 levels with REE
Correlation of resting miR-425 levels with REE between the genotype groups.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Experimental: Low NP Genotype GroupExperimental Treatment4 Interventions
150 healthy adult participants with low NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
Group II: Active Comparator: High NP Genotype GroupExperimental Treatment4 Interventions
50 healthy adult participants with high NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Study diet
2017
N/A
~90

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,943 Previous Clinical Trials
47,797,743 Total Patients Enrolled
University of Alabama at BirminghamLead Sponsor
1,655 Previous Clinical Trials
2,443,913 Total Patients Enrolled
Pankaj Arora, MD, FAHAPrincipal InvestigatorUniversity of Alabama at Birmingham
5 Previous Clinical Trials
1,060 Total Patients Enrolled

Media Library

Glucose Challenge Clinical Trial Eligibility Overview. Trial Name: NCT05216042 — N/A
Cardiovascular Disease Research Study Groups: Experimental: Low NP Genotype Group, Active Comparator: High NP Genotype Group
Cardiovascular Disease Clinical Trial 2023: Glucose Challenge Highlights & Side Effects. Trial Name: NCT05216042 — N/A
Glucose Challenge 2023 Treatment Timeline for Medical Study. Trial Name: NCT05216042 — N/A
Cardiovascular Disease Patient Testimony for trial: Trial Name: NCT05216042 — N/A
~67 spots leftby Apr 2026